GlassScriptPhysician profile
Adriana Posadas
NPI 1104382381
$2,020.95
in general payments reported to CMS, 2019-2025
14 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $569 · 2024: $755 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.68 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $431.97 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $391.31 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $329.92 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $135.50 | 2022-2025 | |
| Amgen INC. | $125.31 | 2024 | Repatha |
| Pfizer INC. | $122.26 | 2023-2024 | |
| Abbvie INC. | $116.28 | 2022-2025 | |
| Myriad Women'S Health, INC. | $115.35 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $110.55 | 2024-2025 | |
| Exact Sciences Corporation | $49.66 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $39.84 | 2022 | |
| Myovant Sciences INC. | $21.97 | 2022 | |
| Aspira Women'S Health INC | $18.63 | 2023 | Ova1 |
| Merck Sharp & Dohme LLC | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Posadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.